Allup Silica Ltd
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 42
- Market Cap
- $7.1M
- Introduction
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Aptose Biosciences Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT04477291
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Southern California, Los Angeles, California, United States
🇺🇸University of Miami, Miami, Florida, United States
A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
- Conditions
- Chronic Lymphocytic LeukemiaNon-Hodgkin's LymphomaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Aptose Biosciences Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03893682
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Pacific Cancer Care, Monterey, California, United States
🇺🇸Torrance Memorial Physician Network, Redondo Beach, California, United States
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Leukemia, Myeloid, AcuteRefractory AMLRelapsed Adult AMLMyelodysplastic Syndrome with Excess Blasts-2Chronic Myelomonocytic Leukemia
- Interventions
- First Posted Date
- 2019-02-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Aptose Biosciences Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT03850574
- Locations
- 🇺🇸
The Kirklin Clinic of UAB Hospital, Birmingham, Alabama, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California Irvine, Irvine, California, United States
A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS
- Conditions
- Acute Myelogenous Leukemia, AdultAcute Myelogenous Leukemia, Relapsed, AdultAcute Myelogenous Leukemia in RelapseHigh Risk MyelodysplasiaAcute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Aptose Biosciences Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT02267863
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸University of California, Irvine, Orange, California, United States
A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours
- Conditions
- Advanced or Metastatic Solid Tumours
- Interventions
- Drug: LOR-253 HCl
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2014-02-25
- Lead Sponsor
- Aptose Biosciences Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01281592
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- Next